Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29686713 | 1.00 | LPL (0.45) | LPLLIPGEGFRNFE2L2CXCR2 | |
| SCHEMBL2658964 | 0.87 | LPL (0.45) | LPLLIPGEGFRNFE2L2CXCR2 | |
| SCHEMBL3810020 | 0.84 | CA2 (0.42) | LPLLIPGEGFRNFE2L2 | |
| SCHEMBL31651983 | 0.83 | LPL (0.40) | LPLLIPGEGFRCXCR2 | |
| SCHEMBL25357432 | 0.83 | LPL (0.41) | LPLLIPGEGFRCXCR2 | |
| SCHEMBL14358557 | 0.83 | LPL (0.41) | LPLLIPGEGFRCXCR2 | |
| SCHEMBL30454415 | 0.83 | LPL (0.41) | LPLLIPGEGFRCXCR2 | |
| SCHEMBL16049143 | 0.83 | LPL (0.41) | LPLLIPGEGFRCXCR2KDM4E | |
| SCHEMBL264121 | 0.82 | LPL (0.39) | LPLLIPGEGFRCXCR2KDM4E | |
| SCHEMBL16760910 | 0.81 | CA1 (0.47) | EGFRNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740948-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 1,3-BENZODIOXOLE DERIVATIVE COMPOUND | Dong Wha Pharm. Co., Ltd. (KR) | 2026-05-13 | — | — | EP | disclosed |
| US-20250059180-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2025-02-20 | — | — | US | disclosed |
| WO-2025008783-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 1,3-BENZODIOXOLE DERIVATIVE COMPOUND | 동화약품주식회사 | 2025-01-09 | — | — | WO | disclosed |
| EP-4464701-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023135564-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 동화약품주식회사 | 2023-07-20 | — | — | WO | disclosed |
| US-20210403485-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AS SELECTIVE TRK INHIBITOR | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| WO-2004062661-A1 | 2-‘5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL!- CARBOXYLIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059180-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CYP2C9, CYP1B1, SULT1A1 | LPL 2984/4885LIPG 3537/4885EGFR 4451/4885 |
| US-20210403485-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AS SELECTIVE TRK INHIBITOR | NTRK1, RET, TTK | LPL 4396/4885LIPG 4638/4885EGFR 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.